SCHEMBL6897984

SCHEMBL6897984

CCCCNC(=O)CN1CCN(CC(=O)NCCCC)CCN(CC(=O)NCCCC)CC1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
SMN1; SMN2 Q16637 2/20 0.53
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
SIGMAR1 Q99720 2/20 0.50
TDP1 Q9NUW8 2/20 0.49
KDM4E B2RXH2 2/20 0.49
TP53 P04637 1/20 0.47
CASP2 P42575 1/20 0.47
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
EPHX1 P07099 2/20 0.45
USP2 O75604 1/20 0.45
NAAA Q02083 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22600490 0.93 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2MEN1KMT2ASIGMAR1
SCHEMBL13032706 0.93 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2MEN1KMT2ASIGMAR1
SCHEMBL2875261 0.91 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2MEN1KMT2ASIGMAR1
SCHEMBL26178992 0.88 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2MEN1KMT2ASIGMAR1
SCHEMBL1900359 0.88 SIGMAR1 (0.67) ALDH1A1SMN1; SMN2MEN1KMT2ASIGMAR1
SCHEMBL27391609 0.88 CASP2 (0.53) ALDH1A1SMN1; SMN2MEN1KMT2ASIGMAR1
SCHEMBL24410021 0.87 MEN1 (0.46) ALDH1A1SMN1; SMN2MEN1KMT2ASIGMAR1
SCHEMBL18623944 0.87 SIGMAR1 (0.54) ALDH1A1SMN1; SMN2MEN1KMT2ASIGMAR1
SCHEMBL29300550 0.87 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MEN1KMT2ASIGMAR1
SCHEMBL7445738 0.86 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MEN1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5874573-A Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy CONCAT, INC. (US) 1999-02-23 US claimed
EP-1382332-A1 Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent Chelator LLC (US) 2004-01-21 EP disclosed
US-6165996-A Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis CONCAT, INC. (US) 2000-12-26 US disclosed
EP-0955044-A2 Method of inhibiting bacterial or fungal growth using a complexing agent CONCAT LTD. (US) 1999-11-10 EP disclosed
EP-0841951-A2 COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS CONCAT LTD. (US) 1998-05-20 EP disclosed
WO-1997001360-A9 COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS 1997-07-17 WO disclosed
WO-1997001360-A2 COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS CONCAT, LTD. (US) 1997-01-16 WO disclosed